Generic Medicine Info
Indications and Dosage
Adult: >17 yr As 0.1% cream: Apply a pea-sized amount to lightly cover the entire face (may include the eyelids) once daily at bedtime.

Mild to moderate plaque psoriasis
Adult: >18 yr As 0.05 or 0.1% cream/gel: Apply a thin layer to the affected lesion(s) once daily in the evening. Initiate at a strength of 0.05% then increase to 0.1% as tolerated. If drying or irritation occurs, apply a moisturiser at least 1 hr before admin of tazarotene. Usual duration of therapy: 12 wk (up to 12 mth if necessary).

Acne vulgaris
Adult: As 0.1% cream/foam: Apply a thin layer to cover the entire affected area(s) once daily in the evening. May use moisturiser as needed. Usual duration of therapy: 12 wk.
Child: ≥12 yr Same as adult dose.
Patient w/ eczema and sunburn. Application to psoriatic lesions >10-20% of BSA. Pregnancy and lactation.
Special Precautions
Patient w/ history of skin cancer.
Adverse Reactions
Significant: Desquamation, pruritus, skin redness, stinging/burning sensation, worsening of psoriasis, swelling at/near application sites, skin discoloration (hyper/hypopigmentation), skin exfoliation and inflammation, hypersensitivity (e.g. urticaria), photosensitivity.
CV: Peripheral oedema.
Endocrine: Hypertriglyceridaemia.
Dermatologic: Erythema, irritation, dermatitis, rash.
Patient Counseling Information
Do not use occlusive dressings. Avoid contact w/ inflamed skin, intertriginous areas, hair-covered scalp, eyes, mouth, and other mucous membranes. Avoid exposure to sunlight or other UV rays.
Monitoring Parameters
Perform pregnancy test w/in 2 wk prior to initiation of therapy and start treatment during a menstrual period.
Drug Interactions
Increased photosensitivity w/ drugs known to be photosensitisers (e.g. fluoroquinolones, tetracyclines, thiazide diuretics, sulfonamides, phenothiazines). Increased risk of irritation w/ use of topical medications and cosmetics w/ irritant or strong drying effects.
Description: Tazarotene, a synthetic acetylenic retinoid, is a prodrug which is converted to tazarotenic acid then binds to 3 retinoic acid receptors but has relative selectivity for RARβ and RARγ. It regulates gene expression, thus modulating cell proliferation, differentiation, and hyperplasia.
Distribution: Plasma protein binding: highly bound as tazarotenic acid (>99%).
Metabolism: Metabolised via esterase hydrolysis to tazarotenic acid and via oxidation to inactive sulfoxides, sulfones, and other polar metabolites.
Excretion: Via urine and faeces. Elimination half-life: Approx 18 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Tazarotene, CID=5381, https://pubchem.ncbi.nlm.nih.gov/compound/Tazarotene (accessed on Jan. 23, 2020)

Store between 20-25°C. Do not freeze. Protect from heat.
MIMS Class
Acne Treatment Preparations / Psoriasis, Seborrhea & Ichthyosis Preparations
ATC Classification
D05AX05 - tazarotene ; Belongs to the class of other antipsoriatics for topical use.
Avage Cream (Allergan, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 13/11/2017.

Buckingham R (ed). Tazarotene. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/11/2017.

Fabior Aerosol (Mayne Pharma LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/11/2017.

Joint Formulary Committee. Tazarotene. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 10/11/2017.

McEvoy GK, Snow EK, Miller J et al (eds). Tazarotene (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 10/11/2017.

Tazorac Cream (Allergan, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 10/11/2017.

Disclaimer: This information is independently developed by MIMS based on Tazarotene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
  • Soritene
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in